.png){kind=icon}
.png){kind=icon}
Return
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
.png){kind=icon}
PRE
AI
Y
D
L
X
Y
M
J
Y
J
K
F
Y
X
Z
J
R
H
Y
R
B
DOI：10.1016/j.cllc.2026.06.003.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• T-DXd showed antitumor activity in patients from China with pretreated HER2m NSCLC • Confirmed ORR was 56.9%, median PFS was 9.9 months, and median OS was 21.0 months • Confirmed ORRs were consistent across subgroups, including HER2 mutation variants • The safety profile was consistent with the known profile of T-DXd • Results support the use of T-DXd in patients from China with pretreated HER2m NSCLC
Journal
IF:
3.3
Papers:
2.4K
Citations:
4.5K
Organization
No organization information available
Cited Papers